Last reviewed · How we verify
Aliskiren Hydrochlorothiazide
Aliskiren hydrochlorothiazide combines a direct renin inhibitor with a thiazide diuretic to lower blood pressure through dual mechanisms of renin-angiotensin system suppression and sodium/fluid reduction.
Aliskiren hydrochlorothiazide combines a direct renin inhibitor with a thiazide diuretic to lower blood pressure through dual mechanisms of renin-angiotensin system suppression and sodium/fluid reduction. Used for Hypertension.
At a glance
| Generic name | Aliskiren Hydrochlorothiazide |
|---|---|
| Sponsor | Novartis |
| Drug class | Direct renin inhibitor / thiazide diuretic combination |
| Target | Renin; sodium-chloride cotransporter (NCCT) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aliskiren directly inhibits renin, the first enzyme in the renin-angiotensin-aldosterone system (RAAS), preventing the conversion of angiotensinogen to angiotensin I and thereby reducing angiotensin II formation. Hydrochlorothiazide is a thiazide diuretic that promotes sodium and water excretion, reducing blood volume and peripheral vascular resistance. Together, these complementary mechanisms provide additive antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Hypokalemia
- Cough
- Headache
Key clinical trials
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension (PHASE4)
- Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension (PHASE4)
- A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients (PHASE3)
- Aldosterone and the Metabolic Syndrome (PHASE1)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aliskiren Hydrochlorothiazide CI brief — competitive landscape report
- Aliskiren Hydrochlorothiazide updates RSS · CI watch RSS
- Novartis portfolio CI